Potential of Tumor Necrosis Factor Inhibitors in Psoriasis and Psoriatic Arthritis

摘要: Objectives To summarize the role of tumor necrosis factor (TNF) in pathogenesis psoriasis and psoriatic arthritis (PsA) to present latest data on efficacy TNF inhibitors these diseases. Data Sources PubMed was used with following indexing terms: , inhibitor etanercept infliximab and/or T cell . Abstract booklets manufacturer's package inserts were also used. When possible, only sources published after year 2000 incorporated. Study Selection that described a for PsA selected based relevance. Clinical trials examined selected. Extraction extracted if they represented safety information, American College Rheumatology criteria improvement, Health Assessment Questionnaire, or response criteria. These abstracted independently by authors. Synthesis Aberrant regulation is involved development PsA. Therefore, recent intervention strategies have incorporated biologic agents specifically target TNF. Etanercept are effective at reducing disease activity generally well tolerated treatment Conclusion Tumor plays major PsA, antagonists provide clinicians worthy alternative traditional therapies, which associated toxic effects poor compliance.